Investor FAQs
Concert Pharmaceuticals, Inc. was incorporated in the State of Delaware on April 12, 2006.
Concert’s headquarters are located at 65 Hayden Avenue, Suite 3000N, Lexington, Massachusetts. The main office phone number is (781) 860-0045.
Concert’s stock is traded on the NASDAQ Global Market under the symbol “CNCE.” The Company’s Initial Public Offering (IPO) was on February 13, 2014.
Our fiscal year ends on December 31.
Our legal counsel is:
Goodwin Procter
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
Our independent auditor is:
Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116
(617) 266-2000
Shares can be purchased through a stockbroker of your choice. Concert does not have a direct stock purchase plan.
Our CUSIP number for Concert’s common stock is 206022 105.
Concert does not expect to declare or pay any cash or other dividends on our common stock. We intend to retain all of our future earnings, if any, to finance the growth and development of our business.
Computershare Trust Company, Inc.
250 Royall Street
Canton, MA 02021
www.computershare.com
US Phone: +1 800 962 4284
International Phone: +1 781 575 3120
If you have misplaced your stock certificates, please contact Concert’s transfer agent,
Computershare Trust Company, Inc.
250 Royall Street
Canton, MA 02021
www.computershare.com
US Phone: +1 800 962 4284
International Phone: +1 781 575 3120
There may be a fee involved for replacing lost stock certificates.
If your shares are held in your name, you must contact our transfer agent, Computershare. If your shares are held in street name, you must contact your broker to update your address.
If you need to speak to Investor Relations regarding your investment or potential investment in Concert’s common stock, you can contact Justine Koenigsberg at (781) 860-0045 or by email at ir@concertpharma.com.
